Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-face trial of topical fluorouracil + calcipotriol dose combinations for actinic keratosis and intraepidermal carcinoma
ACTRN12626001228370Phase 3Not yet recruiting
- Sponsor
- Study, Education and Research Trust Fund
- Start
- Mar 2027
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil and calcipotriol in actinic keratosis (AK), Bowen disease (BD) and cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Study, Education and Research Trust Fund. Primary endpoints: Feasibility of split-face intervention delivery, Recruitment feasibility and 1 more. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
fluorouracilcalcipotriol
03
Conditions
actinic keratosis (AK)Bowen disease (BD)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on ACTRN12626001228370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001228370.